{"id":"W2334177588","doi":"10.1016/j.jpain.2016.01.397","title":"(420) NEO6860, a novel modality selective TRPV1 antagonist: results from a phase I, double-blind, placebo-controlled study in healthy subjects","year":2016,"lang":"en","type":"article","venue":"Journal of Pain","topic":"Ion Channels and Receptors","field":"Neuroscience","cited_by":10,"is_retracted":false,"has_abstract":false,"ca_institutions":"NEOMED Institute","funders":"","keywords":"Medicine; Cmax; Placebo; Adverse effect; Discontinuation; Pharmacokinetics; TRPV1; Pharmacodynamics; Antagonist; Anesthesia; Capsaicin; Pharmacology; Gastroenterology; Internal medicine; Receptor","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001653736,0.001511585,0.00355651,0.0004575235,0.0006003876,0.0007686503,0.001016048,0.002148922,0.004941853],"category_scores_gemma":[0.001097657,0.0008429712,0.001123324,0.0004425364,0.001483732,0.001193082,0.000282347,0.001944921,0.0008130326],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002753004,"about_ca_system_score_gemma":0.0008584928,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001054073,"about_ca_topic_score_gemma":0.002229281,"domain_scores_codex":[0.999414,0.0002377342,0.00005085803,0.0001244227,0.0000508067,0.0001222816],"domain_scores_gemma":[0.9993653,0.0001668282,0.000125787,0.00006111665,0.00007846934,0.0002024762],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.879867,0.01565488,0.000945734,0.00142138,0.001036682,0.0001007726,0.0001368941,0.0002127391,0.07247735,0.00008311351,0.0009119414,0.0271515],"study_design_scores_gemma":[0.6065167,0.3715203,0.01218483,0.00007491551,0.001912524,0.0001863302,0.0001225854,0.0004013387,0.005675796,0.0001525435,0.001199956,0.0000522507],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9869782,0.006393428,0.001706103,0.0002316064,0.000273911,0.001923643,0.001106017,0.0002028727,0.001184217],"genre_scores_gemma":[0.985938,0.005678143,0.001989951,0.000996692,0.0004879801,0.001720955,0.001118191,0.00005801515,0.002012091],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004941853,"threshold_uncertainty_score":0.01653212,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.07433926424854742,"score_gpt":0.3518135080970745,"score_spread":0.277474243848527,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}